CMA LOGISTICS (01292) announces profit forecast, expecting a pre-tax profit of approximately 60 to 70 million yuan for the mid-term.
Chang'an Minsheng Logistics (01292) issued an announcement that, during the six-month period ending on June 30, 2025, the group recorded...
CMA LOGISTICS (01292) announced that during the six-month period ended on June 30, 2025, the Group recorded a profit before tax of approximately RMB 60 million to RMB 70 million (the Group recorded a profit before tax of approximately RMB 43.32 million for the same period in 2024).
The Board believes that the main reasons for the increase in the Group's profit before tax are (1) the company actively exploring new markets and new customers leading to an increase in revenue year-on-year (calculated on a like-for-like basis, the Group's revenue for the first six months of 2024 was approximately RMB 4.165 billion, excluding the revenue of Shenyang Changyou Supply Chain Co., Ltd., which was approximately RMB 420 million for the same period in 2024. After selling its equity stake in Shenyang Changyou in September 2024, the Group no longer consolidates Shenyang Changyou in its financial statements); (2) an increase in gross profit margin year-on-year; and (3) the Group vigorously promoting technological innovation and model innovation, launching the "Extreme Cost Reduction Hurricane Action" cost leadership special project, and strengthening cost and expense control.
Related Articles

AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.

I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.
.png)
Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.
AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.

I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.

Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.
.png)
RECOMMEND

Analysts Respond to Trump’s Dismissal of Fed Governor Cook as a Further Assault on Central Bank Independence
26/08/2025

U.S. Proposes Including Copper, Silicon, Silver on 2025 Critical Minerals List Amid Supply Chain Concerns
26/08/2025

Trump Vows to Slash U.S. Drug Prices by Up to 1500%, Triggering Sell-Off in Pharma Stocks
26/08/2025